SMARCA4/SMARCA2 Inhibitor Dosing Cycles to Limit Cancer Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for targeting the challenges of addressing the challenges of addressing the challenges of addressing the issues of existing technologies have not been solved by the present disclosure relates to the technical problem of addressing the technical problem of addressing the technical problem of not being solved by the present disclosure relates to the technical problem of modulating BRG1- or BRM-associated factors (BAF) complexes, which are essential for gene expression and are overexpressed in cancer cells, leading to uncontrolled proliferation and tumor growth.
Innovation Solution
The administration of a compound, N-(1-((4-(6-(2,6-dimethylmorpholino)pyridin-2-yl)thiazol-2-yl)amino)-3-methoxy-1-oxopropan-2-yl)-1-(methylsulfonyl)-1H-pyrrole-3-carboxamide, or a pharmaceutically acceptable salt thereof, in specific dosing cycles to modulate the activity of BRG1 and BRM, thereby inhibiting cancer cell proliferation and inducing apoptosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If continuous administration of the compound is used to maintain inhibition of BRG1 and BRM, then cancer cell proliferation is suppressed, but toxicity and side effects increase
Solution Approach 1:
The patent implements periodic administration cycles consisting of treatment phases (e.g., 5-14 days of compound administration) followed by interruption phases (e.g., 1-7 days without administration). This periodic dosing schedule maintains therapeutic inhibition of BRG1 and BRM in cancer cells while allowing normal cells to recover, thereby reducing cumulative toxicity and side effects compared to continuous administration
2Productivity
If high dose administration is used to maximize apoptosis induction, then cancer cell death increases, but normal cell damage increases
Solution Approach 1:
The patent employs moderate dosing levels combined with periodic administration rather than continuously high dosing. The treatment phases use sufficient doses to induce apoptosis in cancer cells (achieving partial action on cancer cells), while the interruption phases allow normal cells to recover from sublethal damage, thereby achieving cancer cell death without excessive normal cell damage
3Reliability
If long treatment duration is used to eliminate all cancer cells, then complete remission is achieved, but patient quality of life deteriorates
Solution Approach 1:
The patent structures treatment as alternating phases of administration and interruption over extended periods (e.g., multiple cycles of 5-14 days treatment followed by 1-7 days interruption). This periodic approach maintains long-term therapeutic pressure to achieve complete remission while providing regular interruption periods that improve patient quality of life by reducing cumulative side effects and allowing recovery
Data Source
AI summary
The present disclosure features methods, e.g., dosing regimens, of treating cancer with SMARCA4/SMARCA2 ATPase inhibitors.